SEC Tracker
Get the app

Halozyme Therapeutics HALO

Halozyme Therapeutics: quarterly report for the quarter ended Jun 30, 2023

Form
10-Q
Filed
Period
Importance
Notable
Document
10-Q
Exhibit 10.1
Material contract
Exhibit 10.2
Material contract
Exhibit 10.3
Material contract
Exhibit 10.4
Material contract
Exhibit 10.5
Material contract

Not explained yet; the original is on EDGAR.

View on EDGAR

Open in the app

Get an email when Halozyme Therapeutics files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2836 and related industry codes: the same peer list as the financial tables.

  1. Axsome Therapeutics AXSM public float $4.4B, Jun 30, 2025
  2. Alkermes ALKS public float $4.7B, Jun 30, 2025
  3. Lantheus Holdings LNTH public float $4.3B, Jun 30, 2025
  4. Adma Biologics ADMA public float $4.2B, Jun 30, 2025
  5. Soleno Therapeutics SLNO public float $4.1B, Jun 30, 2025

Data on this page was fetched . The filing on SEC.gov is the record.